A detailed history of Ronald Blue Trust, Inc. transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Ronald Blue Trust, Inc. holds 132 shares of FATE stock, worth $264. This represents 0.0% of its overall portfolio holdings.

Number of Shares
132
Previous 40 230.0%
Holding current value
$264
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 17, 2024

BUY
$3.12 - $5.57 $287 - $512
92 Added 230.0%
132 $0
Q2 2024

Jul 18, 2024

BUY
$3.26 - $7.08 $130 - $283
40 New
40 $0
Q4 2023

Jan 18, 2024

BUY
$1.65 - $3.94 $608 - $1,453
369 New
369 $1,000
Q4 2022

Jan 17, 2023

BUY
$9.86 - $23.83 $936 - $2,263
95 New
95 $2,000

Others Institutions Holding FATE

About FATE THERAPEUTICS INC


  • Ticker FATE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,000,304
  • Market Cap $194M
  • Description
  • Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...
More about FATE
Track This Portfolio

Track Ronald Blue Trust, Inc. Portfolio

Follow Ronald Blue Trust, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ronald Blue Trust, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Ronald Blue Trust, Inc. with notifications on news.